Affiliation:
1. Department of the Chemical-Toxicological and Pharmacological Evaluation of Drugs, Faculty of Pharmacy, Catholic University “Our Lady of Good Counsel”, Tirana,Albania
2. Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Milan, L. Mangiagalli 25, Milan 20133,Italy
Abstract
Background:
Human HDACs represent a group of enzymes able to modify histone and
non-histone proteins, which interact with DNA to generate chromatin. The correlation between irregular
covalent modification of histones and tumor development has been proved over the last decades.
Therefore, HDAC inhibitors are considered as potential drugs in cancer treatment. Romidepsin
(FK228), Belinostat (PXD-101), Vorinostat (SAHA), Panobinostat (LBH-589) and Chidamide were
approved by FDA as novel antitumor agents.
Objective:
The aim of this review article is to highlight the structure-activity relationships of several
FK228 analogues as HDAC inhibitors. In addition, the synergistic effects of a dual HDAC/PI3K
inhibition by some derivatives have been investigated.
Materials and Methods:
PubMed, MEDLINE, CAPLUS, SciFinder Scholar database were considered
by selecting articles which fulfilled the objectives of this review, dating from 2015 till present
time.
Results:
HDAC inhibitors have a significant role in cancer pathogenesis and evolution. Class I
HDAC isoforms are expressed in many tumor types, therefore, potent and selective Class I HDAC
inhibitors are of great interest as candidate therapeutic agents with limited side effects. By structurebased
optimization, several FK228 analogues [15 (FK-A5), 22, 23 and 26 (FK-A11)] were identified,
provided with significant activity against Class I HDAC enzymes and dose dependent antitumor
activity. Compound 26 was recognized as an interesting HDAC/PI3K dual inhibitor (IC50 against
p110α of 6.7 μM while for HDAC1 inhibitory activity IC50 was 0.64 nM).
Conclusion:
Romidepsin analogues HDAC inhibitors have been confirmed as useful anticancer
agents. In addition, dual HDAC/PI3K inhibition showed by some of them exhibited synergistic effects
in inducing apoptosis in human cancer cells. Further studies on FK228 analogues may positively
contribute to the availability of potent agents in tumor treatment.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Reference100 articles.
1. Barneda-Zahonero B.; Parra M.; Histone deacetylases and cancer. Mol Oncol 2012,6(6),579-589
2. Kim H.J.; Bae S.Ch.; Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011,3(2),166-179
3. Ropero S.; Esteller M.; The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007,1(1),19-25
4. Drazic A.; Myklebust L.M.; Ree R.; Arnesen T.; The world of protein acetylation. Biochim Biophys Acta 2016,1864(10),1372-1401
5. Parbin S.; Kar S.; Shilpi A.; Sengupta D.; Deb M.; Rath S.K.; Patra S.K.; Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem 2014,62(1),11-33
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献